AU5010800A - Anti-inflammatory therapy for inflammatory mediated infection - Google Patents
Anti-inflammatory therapy for inflammatory mediated infection Download PDFInfo
- Publication number
- AU5010800A AU5010800A AU50108/00A AU5010800A AU5010800A AU 5010800 A AU5010800 A AU 5010800A AU 50108/00 A AU50108/00 A AU 50108/00A AU 5010800 A AU5010800 A AU 5010800A AU 5010800 A AU5010800 A AU 5010800A
- Authority
- AU
- Australia
- Prior art keywords
- inflammatory
- viral
- agent
- hiv
- group
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/60—Salicylic acid; Derivatives thereof
- A61K31/612—Salicylic acid; Derivatives thereof having the hydroxy group in position 2 esterified, e.g. salicylsulfuric acid
- A61K31/616—Salicylic acid; Derivatives thereof having the hydroxy group in position 2 esterified, e.g. salicylsulfuric acid by carboxylic acids, e.g. acetylsalicylic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/60—Salicylic acid; Derivatives thereof
- A61K31/606—Salicylic acid; Derivatives thereof having amino groups
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
- A61K38/1793—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/20—Interleukins [IL]
- A61K38/2026—IL-4
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/20—Interleukins [IL]
- A61K38/2066—IL-10
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/20—Interleukins [IL]
- A61K38/2086—IL-13 to IL-16
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/02—Drugs for genital or sexual disorders; Contraceptives for disorders of the vagina
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0031—Rectum, anus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0034—Urogenital system, e.g. vagina, uterus, cervix, penis, scrotum, urethra, bladder; Personal lubricants
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US13409199P | 1999-05-14 | 1999-05-14 | |
US60134091 | 1999-05-14 | ||
PCT/US2000/013142 WO2000069255A1 (en) | 1999-05-14 | 2000-05-12 | Anti-inflammatory therapy for inflammatory mediated infection |
Publications (1)
Publication Number | Publication Date |
---|---|
AU5010800A true AU5010800A (en) | 2000-12-05 |
Family
ID=22461735
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
AU50108/00A Abandoned AU5010800A (en) | 1999-05-14 | 2000-05-12 | Anti-inflammatory therapy for inflammatory mediated infection |
Country Status (13)
Country | Link |
---|---|
EP (1) | EP1202620A1 (ko) |
JP (1) | JP2002544210A (ko) |
KR (1) | KR20020024587A (ko) |
CN (1) | CN1353573A (ko) |
AU (1) | AU5010800A (ko) |
BR (1) | BR0010546A (ko) |
CA (1) | CA2368593A1 (ko) |
HK (1) | HK1047216A1 (ko) |
IL (1) | IL146130A0 (ko) |
MX (1) | MXPA01011606A (ko) |
PL (1) | PL351710A1 (ko) |
TR (1) | TR200103271T2 (ko) |
WO (1) | WO2000069255A1 (ko) |
Families Citing this family (17)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
HUP0302068A3 (en) * | 2000-07-20 | 2005-05-30 | Lauras As | Use of cox-2 inhibitors for treating or preventing immunodeficiency and pharmaceutical compositions containing them |
KR20040072720A (ko) * | 2002-01-10 | 2004-08-18 | 파마시아 앤드 업존 캄파니 | 항바이러스제와 함께 사용되는 유두종 바이러스 감염의치료를 위한 cox-2 억제제의 용도 |
AR039540A1 (es) * | 2002-05-13 | 2005-02-23 | Tibotec Pharm Ltd | Compuestos microbicidas con contenido de pirimidina o triazina |
US6790867B2 (en) * | 2002-05-20 | 2004-09-14 | Schering-Plough Animal Health Corporation | Compositions and method for treating infection in cattle and swine |
CN103143022A (zh) * | 2002-07-30 | 2013-06-12 | 奥默罗斯公司 | 眼科冲洗液及方法 |
ITMI20031311A1 (it) * | 2003-06-27 | 2004-12-28 | Indena Spa | Formulazioni per il trattamento di disturbi artrosici. |
DE602004031356D1 (de) * | 2003-11-21 | 2011-03-24 | Zalicus Inc | Verfahren und reagenzien zur behandlung von entzündlichen erkrankungen |
CN102002476B (zh) * | 2010-08-20 | 2013-05-08 | 上海市公共卫生临床中心 | 一种体外培养人体黏膜活组织模型及其建立方法和应用 |
CN102557976B (zh) * | 2010-12-15 | 2015-06-10 | 辽宁盛京制药有限公司 | 溴芬酸有机盐及其制备方法、其组合物及用途 |
EP2481751A1 (en) * | 2011-01-26 | 2012-08-01 | PharmaSurgics in Sweden AB | Human lactoferrin derived peptides |
AU2013201465B2 (en) | 2012-10-24 | 2016-03-03 | Rayner Surgical (Ireland) Limited | Stable preservative-free mydriatic and anti-inflammatory solutions for injection |
CN104013959A (zh) * | 2014-05-21 | 2014-09-03 | 郭和友 | 逆转录抑制剂和免疫抗体细胞三联合疗法 |
CN105456273A (zh) * | 2014-09-02 | 2016-04-06 | 杭州雷索药业有限公司 | 奈韦拉平在制备抗炎药物中的应用 |
TWI705812B (zh) | 2014-12-01 | 2020-10-01 | 奥默羅斯公司 | 用於抑制術後眼睛炎性病況的抗炎和散瞳前房溶液 |
CN106176739A (zh) * | 2016-08-18 | 2016-12-07 | 滨州医学院 | 利托那韦增强糖皮质激素抗炎作用的医药新用途 |
CN106309445A (zh) * | 2016-08-18 | 2017-01-11 | 滨州医学院 | 奈非那韦增强糖皮质激素抗炎作用的医药新用途 |
CN106176751A (zh) * | 2016-08-18 | 2016-12-07 | 滨州医学院 | 茚地那韦增强糖皮质激素抗炎作用的医药新用途 |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5605885A (en) * | 1988-05-05 | 1997-02-25 | Entremed, Inc. | Method for stimulating the immune system |
EP0407701A3 (en) * | 1989-05-15 | 1992-04-22 | Fujisawa Pharmaceutical Co., Ltd. | Antiretroviral pyrroline and pyrrolidine sulfonic acid derivatives |
US5891924A (en) * | 1996-09-26 | 1999-04-06 | Research Development Foundation | Curcumin (diferuloylmethane) inhibition of NFκB activation |
-
2000
- 2000-05-12 JP JP2000617724A patent/JP2002544210A/ja active Pending
- 2000-05-12 IL IL14613000A patent/IL146130A0/xx unknown
- 2000-05-12 AU AU50108/00A patent/AU5010800A/en not_active Abandoned
- 2000-05-12 KR KR1020017014522A patent/KR20020024587A/ko not_active Application Discontinuation
- 2000-05-12 MX MXPA01011606A patent/MXPA01011606A/es not_active Application Discontinuation
- 2000-05-12 WO PCT/US2000/013142 patent/WO2000069255A1/en not_active Application Discontinuation
- 2000-05-12 CA CA002368593A patent/CA2368593A1/en not_active Abandoned
- 2000-05-12 EP EP00932379A patent/EP1202620A1/en not_active Withdrawn
- 2000-05-12 BR BR0010546-5A patent/BR0010546A/pt not_active Application Discontinuation
- 2000-05-12 PL PL00351710A patent/PL351710A1/xx not_active Application Discontinuation
- 2000-05-12 CN CN00807547A patent/CN1353573A/zh active Pending
- 2000-05-12 TR TR2001/03271T patent/TR200103271T2/xx unknown
-
2002
- 2002-12-12 HK HK02109002.5A patent/HK1047216A1/zh unknown
Also Published As
Publication number | Publication date |
---|---|
JP2002544210A (ja) | 2002-12-24 |
KR20020024587A (ko) | 2002-03-30 |
EP1202620A1 (en) | 2002-05-08 |
WO2000069255A1 (en) | 2000-11-23 |
TR200103271T2 (tr) | 2002-06-21 |
CN1353573A (zh) | 2002-06-12 |
MXPA01011606A (es) | 2003-09-10 |
IL146130A0 (en) | 2002-07-25 |
HK1047216A1 (zh) | 2003-02-14 |
CA2368593A1 (en) | 2000-11-23 |
BR0010546A (pt) | 2002-03-05 |
PL351710A1 (en) | 2003-06-02 |
WO2000069255A8 (en) | 2001-03-22 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AU5010800A (en) | Anti-inflammatory therapy for inflammatory mediated infection | |
Klatt | Pathology of AIDS | |
Patterson et al. | Repertoire of chemokine receptor expression in the female genital tract: implications for human immunodeficiency virus transmission | |
Wei et al. | Long-term renal survival in HIV-associated nephropathy with angiotensin-converting enzyme inhibition | |
Utay et al. | Role of immune activation in progression to AIDS | |
Nilsson et al. | Early immune activation in gut-associated and peripheral lymphoid tissue during acute HIV infection | |
Kotler et al. | Effect of combination antiretroviral therapy upon rectal mucosal HIV RNA burden and mononuclear cell apoptosis | |
US20030138399A1 (en) | Anti-inflammatory therapy for inflammatory mediated infection | |
Shacklett et al. | Abundant expression of granzyme A, but not perforin, in granules of CD8+ T cells in GALT: implications for immune control of HIV-1 infection | |
Shen et al. | Mucosal Correlates of Protection in HIV‐1‐Exposed Sero‐negative Persons | |
Rasmussen et al. | Clinical interventions in HIV cure research | |
NIU et al. | Summary of the National Institutes of Health Workshop on Primary Human Immunodeficiency Virus Type 1 Infection1, 2 | |
Johnson et al. | Anti-retroviral therapy reverses HIV-associated abnormalities in lymphocyte apoptosis | |
Van Deventer | Anti-TNF antibody treatment of Crohn's disease | |
Stetson et al. | Eosinophilic dermatoses | |
Purohit et al. | Potential impact of drugs of abuse on mother-to-child transmission (MTCT) of HIV in the era of highly active antiretroviral therapy (HAART) | |
Rogers et al. | Fetal feline immunodeficiency virus is prevalent and occult | |
US8080579B2 (en) | Compositions and methods for treatment of inflammatory bowel disease | |
Schito et al. | A human immunodeficiency virus–transgenic mouse model for assessing interventions that block microbial-induced proviral expression | |
Nair et al. | Association of drug abuse with inhibition of HIV-1 immune responses: studies with long-term of HIV-1 non-progressors | |
Sankatsing et al. | Dynamics of the pool of infected resting CD4 HLA-DR-T lymphocytes in patients who started a triple class five-drug antiretroviral regimen during primary HIV-1 infection | |
EP1194141B1 (en) | Antiviral therapy | |
US6387959B1 (en) | Antiviral therapy | |
US20010053517A1 (en) | Determining nucleic acid sequences in a biological sample | |
Edzeamey et al. | HIV Infection and Therapeutic Interventions: Review on HIV Infection Biology, Highly Active Antiretroviral Therapy (HAARTs), Hepatotoxicity, Nephrotoxicity and Dyslipidemia |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
MK5 | Application lapsed section 142(2)(e) - patent request and compl. specification not accepted |